Blueprint Medicines (BPMC) Tops Q2 EPS by 3c
Get Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.70), $0.03 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $7.07 million versus the consensus estimate of $4.41 million.
Financial Guidance:
Blueprint Medicines expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016. Blueprint Medicines expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into early 2018.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Planet Labs (PL) Reports In-Line Q4 EPS, provides guidance
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
- Surf Air Mobility Inc. (SRFM) Reports revenue, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!